Across TCGA pan-cancer cohorts, ZNF816-ZNF321P Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZNF816-ZNF321P data layer compared with 17 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ZNF816-ZNF321P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF816-ZNF321P expression acts as an unfavorable survival marker.

THYM and OV are the cancer types where ZNF816-ZNF321P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
OV	OS	Median	II,III,IV	0.261	0.843	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ZNF816-ZNF321P tumor-vs-normal RNA expression · all ZNF816-ZNF321P data types